Valuation: Eli Lilly and Company

Capitalization 685B 592B 556B 507B 940B 59,092B 1,061B 6,568B 2,525B 27,122B 2,569B 2,514B 100,070B P/E ratio 2025 *
-
P/E ratio 2026 * -
Enterprise value 710B 613B 576B 525B 974B 61,231B 1,099B 6,806B 2,617B 28,104B 2,662B 2,605B 103,692B EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
99.81%
Yield 2025 *
0.78%
Yield 2026 * 0.87%
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Eli Lilly and Company

1 day+0.32%
1 week-5.95%
Current month+4.47%
1 month+7.75%
3 months-7.99%
6 months+0.38%
Current year-0.18%
More quotes
1 week 755.56
Extreme 755.56
805.16
1 month 714.33
Extreme 714.33
825
Current year 677.09
Extreme 677.0912
935.62
1 year 677.09
Extreme 677.0912
972.53
3 years 296.32
Extreme 296.32
972.53
5 years 129.21
Extreme 129.21
972.53
10 years 64.18
Extreme 64.18
972.53
More quotes
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2016
President - -
Director of Finance/CFO 48 08/09/2024
Director TitleAgeSince
Director/Board Member 64 31/12/2004
Director/Board Member 69 31/03/2009
Director/Board Member 53 11/12/2011
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.04%-5.95%-12.81%+151.28% 685B
+1.02%-3.68%+1.73%-13.90% 360B
-0.83%-3.83%+7.85%+24.53% 327B
-5.29%-12.70%-54.38%+18.36% 326B
+0.46%-3.41%+3.05%-14.83% 255B
+0.20%-2.14%+1.16%+21.00% 228B
+0.27%-5.15%-16.45%+1.13% 217B
+1.39%-1.90%-38.68%-10.09% 199B
-5.84%-7.72%-11.59%+13.45% 156B
+0.25%-2.08%-13.37%-51.03% 136B
Average -0.78%-4.16%-13.35%+13.99% 288.83B
Weighted average by Cap. -0.53%-4.82%-12.87%+37.04%
See all sector performances

Financials

2025 *2026 *
Net sales - -
Net income - -
Net Debt 24.79B 21.41B 20.12B 18.34B 34.03B 2,139B 38.39B 238B 91.41B 982B 92.99B 91.01B 3,622B 12.19B 10.53B 9.89B 9.02B 16.73B 1,052B 18.88B 117B 44.94B 483B 45.72B 44.75B 1,781B
More financial data * Estimated data
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
Employees
47,000
More about the company
Date Price Change Volume
23/06/25 770.64 $ +1.04% 3,948,954
20/06/25 762.73 $ -2.84% 6,210,647
18/06/25 785.03 $ -0.78% 2,442,938
17/06/25 791.24 $ -2.02% 2,875,634

Delayed Quote Nyse, June 23, 2025 at 09:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
Number of Analysts
0
Last Close Price
770.64
Average target price
-
Consensus

Quarterly revenue - Rate of surprise